A*STAR PATENTS
Disclaimer: This database may contain patents not available for licensing.
Patent Number | Patent Title | Abstract |
---|---|---|
Patent NumberUS10514573 | Patent TitleDevice and arrangement for controlling an electromagnetic wave, methods of forming and operating the same | Abstract Various embodiments may provide a device for controlling an electromagnetic wave. The device may include a first electrode layer. The device may also include a second electrode layer. The device may further include a matrix layer between the first electrode layer and the second electrode layer. The matrix layer may include a liquid crystal layer. The matrix layer may also include at least one resonator element in contact with the liquid crystal layer. The liquid crystal layer may be configured to switch from, at least, a first state to a second state in response to a voltage applied between the first electrode layer and the second electrode layer, thereby changing an optical property of the matrix layer to control the electromagnetic wave received by the matrix layer. |
Patent NumberUS10512431 | Patent TitleSensor patch and sensing device having the same | Abstract According to embodiments of the present invention, a sensor patch for detecting extravasation is provided. The sensor patch includes an elastic film, and at least one sensing electrode disposed on the elastic film, wherein an electrical resistance of the at least one sensing electrode is changeable in response to a force acting on the at least one sensing electrode. According to further embodiments of the present invention, a sensing device is also provided. |
Patent NumberUS10500288 | Patent TitleCytotoxic HEXIM1 peptides and uses thereof | Abstract Disclosed are isolated cytotoxic peptides having similar sequences as the basic region (BR) of Hexamethylene Bisacetamide Inducible Protein 1 (HEXIM1). Preferred embodiments include QLGKKKHRRRPSKKKRHW (SEQ ID No: 3). QLGRRRHRRRPSRRRRHW (SEQ ID No: 4) and QLGKKILAARPSKKKRHW (SEQ ID No: 5). Also encompassed are isolated nucleic acid molecules encoding for the claimed peptides, vectors comprising the isolated nucleic acids, compositions comprising peptides conjugated to cell-targeting or penetrating peptides or antibodies, nucleic acid molecules or vectors expressing conjugates thereof; methods of treating or preventing diseases or conditions, including cancers and obesity as well as a method of eliminating undifferentiated stem cells. |
Patent NumberUS10494295 | Patent TitleAnti-reflection coating | Abstract This invention relates to a UV-curable coating material comprising an organosilica compound such as POSS or octahedral oligomeric silsesquioxane which is functionalized with a UV-curable functional group. The material further comprises at least one UV-curable cross-linker. The coating material comprises surface structures in the nano-sized range and can be used in a nanoimprint coating process where the material is coated on a substrate such as glass and a mold is pressed against the material to form an imprint before curing by UV radiation. |
Patent NumberUS10493012 | Patent TitleCosmetic use of heparan sulphate | Abstract Affinity purification of fibroblast growth factor 2-binding heparan sulphate from porcine mucosa (HS8) is disclosed. Also disclosed is a process for the care of keratinous material(s), comprising the application or administration of HS8, or a composition comprising thereof, to keratinous material(s). The composition may be used to improve the condition of skin, such as smoothing the skin, restoring skin elasticity and firmness, or decreasing or preventing wrinkles, and may be formulated for topical or transdermal administration. |
Patent NumberUS10485824 | Patent TitleCationic polyamines for treatment of viruses | Abstract Antiviral cationic polyamines were prepared by modifying polyethylenimines with N-acylating agents that introduce a side chain comprising one or more carbons and at least one alcohol hydroxy group. The cationic polyamines can have a linear or branched polyethylenimine backbone structure. Preferably, the cationic polyamines comprise pendant monosaccharide groups, which can be introduced via a cyclic carbonate comprising a pendant protected monosaccharide (e.g., mannose) group. The cationic polyamines can be active and selective against a broad spectrum of viruses at low concentrations, and are generally non-toxic. |
Patent NumberUS10478058 | Patent TitleSpeckle reduction in optical coherence tomography images | Abstract An optical coherence tomography (OCT) image composed of a plurality of A-scans of a structure is analyzed by defining, for each A-scan, a set of neighboring A-scans surrounding the A-slices scan. Following an optional de-noising step, the neighboring A-scans are aligned in the imaging direction, then a matrix X is formed from the aligned A-scans, and matrix completion is performed to obtain a reduced speckle noise image. |
Patent NumberUS10481307 | Patent TitleOptical antenna | Abstract According to embodiments of the present invention, an optical antenna is provided. The optical antenna includes at least one first particle, and at least one second particle having a diameter that is larger than a diameter of the at least one first particle, wherein the at least one first particle and the at least one second particle are arranged along a plane, and wherein the at least one first particle is configured to enhance an optical emission of at least one light source providing an optical signal to the optical antenna and the at least one second particle is configured to direct the optical signal in a direction at least substantially perpendicular to the plane. |
Patent NumberUS10471091 | Patent TitleHeparan sulphates for use in repair and/or regeneration of skin | Abstract Affinity purification of fibroblast growth factor 2-binding heparan sulphate from porcine mucosa (HS8) is disclosed. Also disclosed is the use of HS8 in repair and regeneration of the skin for treating wounds, burns, ulcers and other skin injuries. |
Patent NumberUS10472626 | Patent TitleModified antimir-138 oligonucleotides | Abstract Disclosed is a modified oligonucleotide capable of reducing or inhibiting one or more activities miR-138. The modified oligonucleotide may comprise at least one locked nucleic acid (LNA) and wherein the oligonucleotide is substantially complementary to a nucleotide sequence of miR-138. Also disclosed are pharmaceutical compositions comprising the oligonucleotides, methods of using the oligonucleotides and uses thereof. |